Evidence map›Paper›PMID 36713517›Full record

ArticleFrontiers in oncology2022

Exceptional response to alectinib for duodenal carcinoma with

Yuri Isaka, Akinori Sasaki, Akira Saito, Yasuaki Motomura, Yayoi Ando, Yoshiaki Nakamura

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yuri IsakaDepartment of Gastroenterology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan.
Akinori SasakiDepartment of Gastroenterology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan.
Akira SaitoDepartment of Pathology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan.
Yasuaki MotomuraDepartment of Gastroenterology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan.
Yayoi AndoClinical Research Support Office, National Cancer Center Hospital Chuou, Tokyo, Japan.
Yoshiaki NakamuraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
National Cancer Center Hospital East · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with advanced duodenal carcinoma usually have a poor prognosis due to limited effective chemotherapy options. The study for genotype-directed therapy in patients with duodenal carcinoma is progressing. However, no clinical data assessing the efficacy of molecularly targeted therapy are presently available. We report the case of a 64-year-old woman who was diagnosed with anaplastic lymphocyte kinase (

Indexed as

alectinibduodenal cancerEML4-ALK rearrangementgastrointestinal cancernext-generation sequencing

Identifiers

PMID36713517
PMCPMC9878825
OpenAlexW4315651773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.